INSERM UMR 1069, Nutrition Croissance et Cancer, Université de Tours, Tours, France.
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1413-1428. doi: 10.1002/jcsm.12633. Epub 2020 Oct 14.
Research investigators have shown a growing interest in investigating alterations underlying skeletal muscle wasting in patients with cancer. However, skeletal muscle dysfunctions associated with cancer cachexia have mainly been studied in preclinical models. In the present review, we summarize the results of clinical studies in which skeletal muscle biopsies were collected from cachectic vs. non-cachectic cancer patients. Most of these studies suggest the presence of significant physiological alterations in skeletal muscle from cachectic cancer patients. We suggest a hypothesis, which connects structural and metabolic parameters that may, at least in part, be responsible for the skeletal muscle atrophy characteristic of cancer cachexia. Finally, we discuss the importance of a better standardization of the diagnostic criteria for cancer cachexia, as well as the requirement for additional clinical studies to improve the robustness of these conclusions.
研究人员对癌症患者骨骼肌减少的潜在变化越来越感兴趣。然而，与癌症恶病质相关的骨骼肌功能障碍主要在临床前模型中进行了研究。在本综述中，我们总结了从恶病质与非恶病质癌症患者中采集骨骼肌活检的临床研究结果。这些研究大多表明，恶病质癌症患者的骨骼肌存在显著的生理变化。我们提出了一个假设，将可能至少部分导致癌症恶病质特征性骨骼肌萎缩的结构和代谢参数联系起来。最后，我们讨论了更好地标准化癌症恶病质诊断标准的重要性，以及需要进行更多的临床研究来提高这些结论的可靠性。
